Response to Ursodeoxycholic Acid May Be Assessed Earlier to Allow Second-Line Therapy in Patients with Unresponsive Primary Biliary Cholangitis.
Guilherme Grossi Lopes CançadoCláudia Alves CoutoDebora Raquel Benedita TerrabuioEduardo Luiz Rachid CançadoCristiane Alves Villela-NogueiraMaria Lucia Gomes FerrazMichelle Harriz BragaMateus Jorge NardelliLuciana Costa FariaNathalia Mota de Faria GomesElze Maria Gomes OliveiraVivian RotmanMaria Beatriz OliveiraSimone Muniz Carvalho Fernandes da CunhaMarlone Cunha-SilvaLiliana Sampaio Costa MendesClaudia Alexandra Pontes IvantesLiana CodesValéria Ferreira de Almeida E BorgesFabio Heleno de Lima PaceMario Guimarães PessoaLaura Vilar GuedesIzabelle Venturini SignorelliGabriela Perdomo CoralCynthia LevyPaulo Lisboa Bittencourtnull nullPublished in: Digestive diseases and sciences (2022)
After 6 months of treatment with UDCA, the absence of response by different criteria could properly identify patients who could benefit from early addition of second-line therapies, especially in patients with advanced disease or high baseline liver enzymes levels.
Keyphrases